Conduit Pharmaceuticals (CDT) Competitors

Unity Biotechnology (NASDAQ:UBX) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Do institutionals & insiders hold more shares of UBX or CDT?

29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 5.8% of Unity Biotechnology shares are held by company insiders. Comparatively, 4.1% of Conduit Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media favor UBX or CDT?

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Unity Biotechnology. MarketBeat recorded 2 mentions for Conduit Pharmaceuticals and 1 mentions for Unity Biotechnology. Unity Biotechnology's average media sentiment score of 1.89 beat Conduit Pharmaceuticals' score of 0.71 indicating that Unity Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Unity Biotechnology	Very Positive
Conduit Pharmaceuticals	Positive

Which has more risk & volatility, UBX or CDT?

Unity Biotechnology has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Does the MarketBeat Community prefer UBX or CDT?

Unity Biotechnology received 181 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 66.91% of users gave Unity Biotechnology an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 182 66.91%	Underperform Votes 90 33.09%
Conduit Pharmaceuticals	Outperform Votes 1 100.00%	Underperform Votes No Votes

Is UBX or CDT more profitable?

Conduit Pharmaceuticals' return on equity of 0.00% beat Unity Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Conduit Pharmaceuticals	N/A	N/A	-328.67%

Which has stronger valuation & earnings, UBX or CDT?

Conduit Pharmaceuticals has lower revenue, but higher earnings than Unity Biotechnology. Unity Biotechnology is trading at a lower price-to-earnings ratio than Conduit Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	63.07	-$39.86M	-$1.62	-0.54
Conduit Pharmaceuticals	N/A	N/A	-$540K	-$534.48	0.00

Do analysts recommend UBX or CDT?

Unity Biotechnology presently has a consensus target price of $3.75, indicating a potential upside of 326.38%. Given Unity Biotechnology's higher probable upside, equities research analysts clearly believe Unity Biotechnology is more favorable than Conduit Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Conduit Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Unity Biotechnology beats Conduit Pharmaceuticals on 9 of the 17 factors compared between the two stocks.